[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100543759":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":39,"centralContacts":43,"locations":48,"responsibleParty":64,"collaborators":30,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":30,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":30,"enrollmentInfo":75,"targetDuration":30,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":30,"overallStatus":51,"whyStopped":30,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Peking University Cancer Hospital & Institute","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"1","EXPERIMENTAL","Adebrelimab（1200mg iv q3w） plus Apatinib(250mg po qd)",[13],"Drug: Adebrelimab plus Apatinib",{"label":15,"type":10,"description":16,"interventionNames":17},"2","Adebrelimab（1200mg iv q3w）plus Bevacizumab(15mg\u002Fkg iv q3w)",[18],"Drug: Adebrelimab plus Bevacizumab",{"label":20,"type":10,"description":21,"interventionNames":22},"3","Camrelizumab (200mg iv q2w) plus Apatinib(250mg po qd)",[23],"Drug: Camrelizumab plus Apatinib",[25,31,35],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","Adebrelimab plus Apatinib","Adebrelimab 1200mg intravenously every 3 weeks plus Apatinib 250mg orally once daily",[9],null,{"type":26,"name":32,"description":33,"armGroupLabels":34,"otherNames":30},"Adebrelimab plus Bevacizumab","Adebrelimab 1200mg intravenously plus Bevacizumab 15 mg\u002Fkg intravenously every 3 weeks",[15],{"type":26,"name":36,"description":37,"armGroupLabels":38,"otherNames":30},"Camrelizumab plus Apatinib","camrelizumab 200mg intravenously every 2 weeks plus Apatinib 250mg orally once daily",[20],[40],{"name":41,"affiliation":5,"role":42},"Jun Zhou","PRINCIPAL_INVESTIGATOR",[44],{"name":41,"role":45,"phone":46,"phoneExt":30,"email":47},"CONTACT","13366152815","Joelbmu@126.com",[49],{"facility":50,"status":51,"city":52,"state":53,"zip":30,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"Beijing Cancer Hospital","RECRUITING","Beijing","Beijing Municipality","China","CN",{"type":57,"coordinates":58},"Point",[59,60],116.39723,39.9075,{"lat":60,"lon":59},[63],{"name":41,"role":45,"phone":46,"phoneExt":30,"email":47},{"type":65,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100543759","phase-2-anti-pd-1pd-l1-combined-with-anti-angiogenic-agents-as-first-line-treatment-for-unresectable-hcc-100543759",false,"NCT06360042","Anti-PD-1\u002FPD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC","Anti-PD-1\u002FPD-L1 Combined With Anti-angiogenic Agents as First-line Therapy for Unresectable Hepatocellular Carcinoma: a Multicenter, Randomized, Open-label Trial","Inclusion Criteria:\n\n* Locally advanced or metastatic and\u002For unresectable Hepatocellular Carcinoma (HCC)\n* No prior systemic therapy for HCC. Previous use of herbal therapies\u002Ftraditional Chinese medicines with anti-cancer activity included in the label is allowed.\n* BCLC stage B or C, and not suitable for surgical or local therapy, or has progressed following surgical and\u002For local therapy\n* At least one measurable lesion per RECIST v1.1\n* ECOG Performance Status of 0 or 1\n* Child-Pugh class of A5 to B7\n* Adequate organ function\n\nExclusion Criteria:\n\n* Known hepatocholangiocarcinoma, sarcomatoid HCC, mixed cell carcinoma and lamellar cell carcinoma; other active malignant tumor except HCC within 5 years or simultaneously\n* Moderate-to-severe ascites with clinical symptoms\n* History of gastrointestinal hemorrhage within 6 months prior to the start of study treatment or clear tendency of gastrointestinal hemorrhage\n* Abdominal fistula, gastrointestinal perforation or intraperitoneal abscess within 6 months prior to the start of study treatment\n* Known genetic or acquired hemorrhage or thrombotic tendency\n* Thrombosis or thromboembolic event within 6 months prior to the start of study treatment\n* Hypertension that can not be well controlled through antihypertensive drugs Factors to affect oral administration\n* History of hepatic encephalopathy\n* Previous or current presence of metastasis to central nervous system","ALL","18 Years",{"count":76,"type":77},111,"ESTIMATED","INTERVENTIONAL",[80],"PHASE2","This is a multicenter, randomized, open-label clinical study to evaluate the efficacy and safety of Adebrelimab plus Apatinib (cohort 1), or Adebrelimab plus Bevacizumab (cohort 2), or Camrelizumab plus Apatinib (cohort 3) as first-line treatment of unresectable HCC.",[83],"Unresectable Hepatocellular Carcinoma","2024-04-19",{"date":86,"type":87},"2024-04-22","ACTUAL",{"date":89,"type":87},"2024-01-01",{"date":91,"type":77},"2028-03-31",{"name":5,"class":6},1]